Singapore markets closed
Straits Times Index
3,290.70 +24.75 (+0.76%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,963.68 +425.87 (+2.30%) FTSE 100
8,433.76 +52.41 (+0.63%) Bitcoin USD
60,729.95 -2,462.46 (-3.90%) CMC Crypto 200
1,261.13 -96.88 (-7.13%)
Phio Pharmaceuticals Corp. (PHIO)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Currency in USD
Valuation measures4
| Market cap (intra-day) | 3.23M |
| Enterprise value | -5.22M |
| Trailing P/E | 0.18 |
| Forward P/E | 0.31 |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | 48.01 |
| Price/book (mrq) | 0.42 |
| Enterprise value/revenue | 172.20 |
| Enterprise value/EBITDA | 0.61 |
Trading information
Stock price history
| Beta (5Y monthly) | 1.37 |
| 52-week change 3 | -79.08% |
| S&P500 52-week change 3 | 26.27% |
| 52-week high 3 | 6.8500 |
| 52-week low 3 | 0.5000 |
| 50-day moving average 3 | 0.7847 |
| 200-day moving average 3 | 1.1875 |
Share statistics
| Avg vol (3-month) 3 | 422.12k |
| Avg vol (10-day) 3 | 157.97k |
| Shares outstanding 5 | 4.59M |
| Implied shares outstanding 6 | 4.59M |
| Float 8 | 4.55M |
| % held by insiders 1 | 0.59% |
| % held by institutions 1 | 11.04% |
| Shares short (30 Apr 2024) 4 | 184.69k |
| Short ratio (30 Apr 2024) 4 | 0.43 |
| Short % of float (30 Apr 2024) 4 | 4.05% |
| Short % of shares outstanding (30 Apr 2024) 4 | 4.02% |
| Shares short (prior month 28 Mar 2024) 4 | 21.39k |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | 15 Jan 2020 |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | 1:12 |
| Last split date 3 | 26 Jan 2023 |
Financial highlights
Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Dec 2023 |
Profitability
| Profit margin | 0.00% |
| Operating margin (ttm) | 0.00% |
Management effectiveness
| Return on assets (ttm) | -59.86% |
| Return on equity (ttm) | -116.60% |
Income statement
| Revenue (ttm) | N/A |
| Revenue per share (ttm) | N/A |
| Quarterly revenue growth (yoy) | N/A |
| Gross profit (ttm) | N/A |
| EBITDA | -10.56M |
| Net income avi to common (ttm) | -10.83M |
| Diluted EPS (ttm) | -5.2000 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 8.49M |
| Total cash per share (mrq) | 1.85 |
| Total debt (mrq) | 35k |
| Total debt/equity (mrq) | 0.45% |
| Current ratio (mrq) | 5.70 |
| Book value per share (mrq) | 2.06 |
Cash flow statement
| Operating cash flow (ttm) | -10.75M |
| Levered free cash flow (ttm) | -6.53M |
© 2024 Yahoo. All rights reserved.